Antengene Shares New ATG-022 and ATG-037 Clinical Data at ESMO
Antengene presented clinical updates for ATG-022 in gastric and gastroesophageal junction cancers and ATG-037 with pembrolizumab in checkpoint inhibitor-resistant melanoma at ESMO 2026. The company described the combination’s efficacy as robust and durable, with favorable safety.